Barclays’s Vivos Therapeutics VVOS Stock Holding History

Barclays’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$3	–	5563
2025 Q1	$3	Buy	+1	New	+$4	﹤0.01%	5207

Other funds holding VVOS

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Barclays's VVOS Position: Q2 2025 in Review

Barclays sold out of Vivos Therapeutics (VVOS) in Q2 2025, closing a stake of 1 share — an estimated $3 sold.

Barclays first reported a position in VVOS in Q1 2025 and held it in 1 quarter. The position peaked at $3 in Q1 2025. 19 funds tracked by Wall St. Rank hold VVOS as of Q2 2025.

Barclays reported no remaining Vivos Therapeutics position as of Q2 2025 after selling out during the quarter.
Barclays sold 1 Vivos Therapeutics share in Q2 2025, an estimated $3.
Barclays first reported a position in Vivos Therapeutics in Q1 2025 and held it in 1 quarter.
Barclays's Vivos Therapeutics position peaked at $3 in Q1 2025.
19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.